IV Sets, Let’s talk Filters
By: Health Line Marketing—June 2020
Anyone who is in the business of administering fluids via IV sets understands the importance of a quality IV set filter. We understand that at Health Line and offer quality filters composed of is polyethersulfone (PES). The sizes of the membrane pore are 0.22 μm and 1.2 μm selectable and the size remains consistent during infusion. The multiple layer, three-dimensional filter, significantly increases the capability of entrapping microparticles and reduces drug absorption rate; and there is no membrane shedding. This helps prevent phlebitis, vascular discoloration or hardening, local embolisms, scleroma, limb numbness, granuloma, etc. thus ensuring a safe, clinical infusion.
Comparing Filter Materials:
Ordinary Filter Membrane
General Filter Membrane
Health Line Filter Membrane
Hydrophilic group shed during
Repeated holes may enable
- American Infusion Nurses Society (INS) indicated that non-lipid solutions need to use a precision filter with filtering pore size 0.2μm, while lipid solutions and full parenteral nutrition mixtures need to use a precision filter with filtering pore size 1.2μm(1). 2. “Intravenous Infusion Treatment Nursing” indicated that with filters of pore size 0.2 μm articles and bacteria and other microorganisms can be filtered so that endotoxin and heat source reaction are reduced(2). 3. Scholarly researchers suggest using the precision filter with filter pore size 0.2μm for non-lipid solutions and filter size 1.2μm for lipid solutions and full parenteral nutrition mixtures (3,4,5).
Health Line’s Flow Controller provides a constant flow rate during the entire infusion procedure. There is no need for continuous adjustment of flow rate and there is no risk of over-infusion. Because it takes two hands to set and adjust our products, this prevents accidental changes in flow. Infusion Nurthree-dimensionalities and Procedures for Infusion Therapy Indicated that manual flow control devices may be used for infusions that do not require strict control.
Seeking Distribution Partner in Japan
By: Health Line Sales-February 2017
We are actively searching for a distribution partner in Japan to import our medical devices.
Please contact our customer service team at firstname.lastname@example.org to become a distributor or send in a recommendation.
Choosing a Midline Catheter
5 Things to Consider
By: Health Line Marketing—March 2018
1. Consider infusate characteristics in conjunction with anticipated duration of treatment (eg, 1-4 weeks.)
2. Consider a midline catheter for medications, and solutions, such as antimicrobials, fluid replacement, and analgesics with characteristics that are well tolerated by peripheral veins.
3. Do not use midline catheters for continuous vesicant therapy, parenteral nutrition, or infusates with an osmolarity greater than 900 mOsm/L.
4. Use caution with intermittent vesicant administration due to risk of undetected extravasation. The administration of vancomycin for less than 6 days through a midline catheter was found to be safe in one study.
5. Avoid the use of a midline catheter when the patient has a history of thrombosis, hypercoagulability, decreased venous flow to the extremities, or end-stage renal disease requiring vein preservation.
Source: Journal of Infusion Nursing Volume 39,Number 1S
Health Line International Corp. is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.
Using PICCs in Cancer Patients
By: Health Line Sales and Marketing -January 2017
A study completed comparing the safeness and effectiveness of using Health Line peripherally inserted central catheters (PICCs) in place of central venous catheters for various cancer treatments confirms PICCs are a “safe venous device for chemotherapy delivery.”
Synergy CT PICC lines were implanted into a total of 291 cancer patients receiving “chemotherapy and/or associated supportive nutritional therapy at fixed intervals of time” depending on the patient.
The study was done from January 1, 2012, to June 1, 2014, and concluded,
PICCs can be considered safe and reliable to deliver chemotherapy in particular during the early 2-3 months after implant. Nevertheless, physicians must be aware that failure may over in almost 15% of them, thus potentially overcoming the majority of PICC claimed advantages. Chemotherapy patients with risk factors with failure, in particular, previous DVT of the necessity of larger than 5F catheters, should be considered for an alternative vascular access device.”
For access to the full article, contact one of Health Line’s representatives.
Source: Sergio Bertogliom Beatrice Faccini, Luca Lallo, Ferdinando Cafiero and Paolo Bruzzi. "Peripherally Inserted Central Catheters (PICCs) in Cancer Patients Under Chemotherapy: A Prospective Study on the Incidence of Complications and Overall Failures." Journal of Surgical Oncology, 2016 (1-7).
Page 1 of 2